|

Initial Double Sequential External Defibrillation in Out of Hospital Cardiac Arrest

RECRUITINGN/ASponsored by St. Olavs Hospital
Actively Recruiting
PhaseN/A
SponsorSt. Olavs Hospital
Started2025-04-28
Est. completion2028-06
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06672159

Summary

Double Sequential External Defibrillation (DSED) represents an alternative treatment of refractory ventricular fibrillation (rVF) in out-of-hospital cardiac arrest (OHCA). The procedure consists of two defibrillators that administer shocks at the same time. Currently, the procedure is not initiated before at least three failed attempts with one defibrillator. This can delay the potential benefits of establishing DSED earlier in the treatment. Studies have shown that early defibrillation is crucial for survival in OHCA patients, and in 2022, a clinical trial showed that survival in patients treated with DSED was higher compared to standard treatment. The effect of initiating OHCA treatment is unknown. The DUALDEFIB trial seeks to investigate if treating OHCA patients with DSED as an initial treatment will increase survival and provide improved neurological outcome.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with out of hospital cardiac arrest presenting with a shockable rhythm

Exclusion Criteria:

* Age below 18 years
* Obvious or suspected pregnancy
* Incarcerated patients
* Preexisting do-not-resuscitate order

Conditions4

Cardiac ArrestHeart DiseaseOut-Of-Hospital Cardiac ArrestVentricular Fibrillation

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.